Univerity of Nevada Las Vegas, Las Vegas, NV, 89154, United States of America.
Life Sci Space Res (Amst). 2024 Feb;40:166-175. doi: 10.1016/j.lssr.2023.08.003. Epub 2023 Aug 23.
Future space travel to the earth's moon or the planet Mars will likely lead to the selection of experienced International Space Station (ISS) or lunar crew persons for subsequent lunar or mars missions. Major concerns for space travel are galactic cosmic ray (GCR) risks of cancer and circulatory diseases. However large uncertainties in risk prediction occur due to the quantitative and qualitative differences in heavy ion microscopic energy deposition leading to differences in biological effects compared to low LET radiation. In addition, there are sparse radiobiology data and absence of epidemiology data for heavy ions and other high LET radiation. Non-targeted effects (NTEs) are found in radiobiology studies to increase the biological effectiveness of high LET radiation at low dose for cancer related endpoints. In this paper the most recent version of the NASA Space Cancer Risk model (NSCR-2022) is used to predict mission risks while considering NTEs in solid cancer risk predictions. I discuss predictions of space radiation risks of cancer and circulatory disease mortality for US Whites and US Asian-Pacific Islander (API) populations for 6-month ISS, 80-day lunar missions, and combined ISS-lunar mission. Model predictions suggest NTE increase cancer risks by about ∼2.3 fold over a model that ignores NTEs. US API are predicted to have a lower cancer risks of about 30% compared to US Whites. Cancer risks are slightly less than additive for multiple missions, which is due to the decease of risk with age of exposure and the increased competition with background risks as radiation risks increase. The inclusion of circulatory risks increases mortality estimates about 25% and 37% for females and males, respectively in the model ignoring NTEs, and 20% and 30% when NTEs are assumed to modify solid cancer risk. The predictions made here for combined ISS and lunar missions suggest risks are within risk limit recommendations by the National Council on Radiation Protection and Measurements (NCRP) for such missions.
未来前往地球月球或火星的太空旅行可能会选择有经验的国际空间站 (ISS) 或月球机组人员执行后续的月球或火星任务。太空旅行的主要关注点是银河宇宙射线 (GCR) 引发癌症和循环系统疾病的风险。然而,由于重离子微观能量沉积的定量和定性差异导致与低 LET 辐射相比生物效应存在差异,因此风险预测存在很大的不确定性。此外,对于重离子和其他高 LET 辐射,还缺乏放射生物学数据和流行病学数据。非靶向效应 (NTE) 在放射生物学研究中被发现可提高高 LET 辐射在低剂量下对癌症相关终点的生物学效应。本文使用美国宇航局 (NASA) 最新版本的太空癌症风险模型 (NSCR-2022) 来预测任务风险,同时考虑非靶向效应在实体癌风险预测中的作用。我讨论了 6 个月 ISS、80 天月球任务和 ISS-月球联合任务中美国白人和美国亚太裔 (API) 人群的癌症和循环系统疾病死亡率的空间辐射风险预测。模型预测表明,与忽略 NTE 的模型相比,NTE 使癌症风险增加了约 2.3 倍。与美国白人相比,美国 API 的癌症风险预计要低约 30%。由于暴露年龄与风险的降低以及随着辐射风险的增加与背景风险的竞争增加,因此多次任务的癌症风险略低于加性风险。在忽略 NTE 的模型中,包括循环系统风险会使女性和男性的死亡率估计分别增加约 25%和 37%,而当假设 NTE 会改变实体癌风险时,女性和男性的死亡率估计则分别增加 20%和 30%。这里对 ISS 和月球联合任务的预测表明,这些任务的风险在国家辐射防护和测量委员会 (NCRP) 的风险限制建议范围内。